Esplorando il design di farmaci con IA, farmacologia computazionale e biologia programmabile.
Modelli generativi, AlphaFold e machine learning che accelerano la scoperta molecolare.
FEP, dinamica molecolare, calcolo quantistico e criomicroscopia nell'ottimizzazione dei candidati.
PROTAC, proteine programmabili, profarmaci e ADC di nuova generazione.
Quadri FDA-EMA, analisi di mercato ed economia della scoperta di farmaci con IA.
A comprehensive analysis of how generative AI models are transforming de novo molecular design, with the latest methods, tools, and clinical implications.
How DeepMind's AlphaFold 3 is revolutionizing structure-based drug design through protein-ligand complex prediction.
Exploring how AI platforms like PandaOmics identify novel drug targets and accelerate their journey to clinical trials.
A comprehensive guide to ML-based ADMET prediction methods, tools, and their role in reducing late-stage drug failures.
A detailed case study of rentosertib (INS018_055), the first AI-designed drug to reach Phase III clinical trials.
An in-depth analysis of FEP methods for predicting binding free energies and their transformative role in lead optimization.